NV-5138

Supernus Pharmaceuticals' SPN-820, an mTORC activator for treatment-resistant depression, failed to demonstrate statistical significance against placebo in Phase IIb study, showing only a marginal 0.4-point difference in MADRS scores.

Supernus Pharmaceuticals announces significant label updates for their non-stimulant ADHD medication Qelbree®, including new pharmacodynamic data detailing its serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition. The medication becomes the first ADHD treatment to meet FDA's 2019 guidance requirements for clinical lactation studies.

Supernus Pharmaceuticals' SPN-820, a novel mTORC1 modulator, demonstrated safety and efficacy as an adjunctive treatment for major depressive disorder in a Phase IIa trial.